199730.Kq
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.72, indicating a moderate reliance on debt financing. However, its liquidity position is weak, with a current ratio of 0.69, suggesting that the company may struggle to meet its short-term obligations. The company's cash and equivalents amount to 2,144,235,820 KRW, which is significantly lower than its long-term debt of 11,857,493,720 KRW, resulting in a negative net cash position.
Profitability metrics reveal a challenging financial situation. The company reported a net loss of 9,131,042,240 KRW, with a return on equity of -55.37% and a return on assets of -26.12%. These figures are well below the industry norms for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and utilizing its assets efficiently.
The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment reporting suggests that the company may be heavily reliant on a few key products or markets, which could pose a risk to its financial stability if those areas experience downturns.
Looking ahead, the company's growth trajectory is uncertain. The absence of specific outlook data for the current and next fiscal years means that there is no clear indication of expected revenue changes or operational improvements. The company's negative operating and net income, combined with negative operating and free cash flows, suggest that it is currently in a contractionary phase and may require significant operational or strategic changes to return to growth.
The company faces several risk factors, including its weak liquidity position and the potential for dilution. The risk assessment indicates a medium level of liquidity risk, primarily due to the company's inability to cover its short-term liabilities with its current assets. While the risk of dilution is currently low, the company's negative net cash position and high debt levels could necessitate future equity issuances, which would dilute existing shareholders.
Recent events and filings do not provide specific details about the company's operations or financial strategy. The lack of recent transcripts or detailed filings suggests that the company may not be actively communicating its strategic direction or financial performance to the public, which could limit investor confidence and market visibility.
- The company is experiencing significant financial distress, as evidenced by its negative net income and return on equity.
- The company's liquidity position is weak, with a current ratio below 1 and a negative net cash position.
- The company's profitability metrics are well below industry norms, indicating poor performance relative to its peers.
- The company's growth trajectory is uncertain, with no clear indication of expected revenue changes or operational improvements.
- The company faces medium liquidity risk and potential dilution if it needs to raise additional capital.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 199730.KQ Market data — financials · 2026-05-26